Thomas F. Lüscher/LinkedIn
Aug 5, 2026, 14:25
Thomas F. Lüscher: ZEUS Trial Highlights the Challenge of Translating Anti-Inflammatory Effects into Clinical Benefit
Thomas F. Lüscher, Director of Research, Education and Development and Consultant of Cardiology at Royal Brompton and Harefield Hospitals, shared a post on LinkedIn:
“ZEUS has been angry: Ziltivekimab reduced IL-6 and hsCRP, but did not translate into MACE risk reduction versus placebo in patients with ASCVD, CKD and inflammation (HR 0.99; CI 0.88-1.11) – will Artemis (AMI) and Hermes (HfpEF) be in better mood?
It is important to continue with these trials as CKD patients may be different, too late in the course of CVD to make a difference with IL-6 blockade.”
Stay updated with Hemostasis Today.
-
Sep 25, 2026, 10:49Shefina S: From Presenting to Hosting at TRANSCON 2026
-
Sep 25, 2026, 10:37Michelle Leona Cecil: Hemophilia Advocacy and the Power of Community
-
Sep 25, 2026, 10:13Michael Baria: Platelet Concentration and PRP Outcomes in Partial Rotator Cuff Tears
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event